BrightInsight Named 2023 Global Company of the Year by Frost & Sullivan for Enabling Better Patient Outcomes with Digital Solutions

BrightInsight’s Platform and out-of-the-box Disease Management Solution speed time to market for patient apps, enabling biopharma to differentiate their therapies, improve conversion and enhance the patient experience.

SAN ANTONIO, May 23, 2023 /PRNewswire/ — Frost & Sullivan recently analyzed the healthcare Internet of Things (IoT) solutions industry and based on its findings, recognizes BrightInsight, a software-as-a-service (SaaS) provider accelerating compliant digital health innovation, with the 2023 Global Company of the Year Award. BrightInsight partners with biopharma and medtech companies to rapidly build, maintain, and scale compliant companion apps, Software as a Medical Device (SaMD) solutions, algorithms, and analytics dashboards that aim to improve clinical outcomes and enhance the patient journey.

As patients continue to expect personalized digital support tools for their therapy, biopharma and medtech companies are developing SaMD and patient-facing apps. Customized to address specific patient pain points and brand challenges, apps can increase first-fill rates, adherence and persistence, decrease churn and garner more brand loyalty.

BrightInsight’s platform accelerates the development of these solutions and enables biopharma companies to easily tailor the features and languages for their brands and target regions. Additionally, its web-based portal makes deploying clinician web portals and integration with electronic health records (EHR) simpler and more straightforward. Built from the ground up with compliance and scalability at the forefront, BrightInsight’s SaaS infrastructure provides its biopharma and medtech customers with an efficient and de-risked way to iterate, launch and expand their patient app offerings over time.

Amartya Bose, industry analyst at Frost & Sullivan, noted, “BrightInsight’s modular platform and configurable Disease Management Solution enable biopharma and MedTech customers to get an app or SaMD to market quickly and scale over time to drive clinical and business results while delivering cost efficiencies.”

BrightInsight has worked with many of the leading global biopharma, MedTech and in vitro diagnostics (IVD) companies including Sanofi, Roche, Novo Nordisk, CSL Behring and bioMerieux, and has completed 18 SaMD projects across diverse therapy areas and pain points. Its team has over 340 years of combined SaMD experience and ensures compliance with global security, privacy, and regulatory requirements. The company has completed over 45 regulatory audits and invested on average over 500 hours per audit to ensure regulatory compliance for each customer. Most recently, BrightInsight supported a customer in achieving its CE-mark approval for a companion patient app. BrightInsight’s corporate culture puts customer satisfaction at the center, driving customer loyalty, its Net Promoter Score (NPS) and revenue growth.

“BrightInsight addresses customer pain points through a strong focus on improving the patient journey and exemplifies best practices in implementation, ensuring a smooth go-to-market process to drive patient and clinician adoption. The company’s proven unified solution combined with the extensive knowledge of the team, ensures speed, compliance, and scalability, differentiating BrightInsight as a trusted partner to biopharma and MedTech, with a reputation for offering the overall best in the healthcare IoT market,” added Ojaswi Rana, best practices research analyst at Frost & Sullivan.

Each year, Frost & Sullivan presents a Company of the Year Award to the organization that demonstrates excellence in terms of growth strategy and implementation in its field. The award recognizes a high degree of innovation with products and technologies, and the resulting leadership in terms of customer value and market penetration.

Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan

For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Contact:
Ashley Weinkauf
P: 210-844-2505
E: [email protected]

About BrightInsight:

BrightInsight provides the leading global platform for biopharma and MedTech regulated digital health solutions. When speed matters, we help companies accelerate time to market for regulated digital health offerings across therapeutic areas, including apps, healthcare provider interfaces, analytics dashboards, algorithms, medical devices, connected combination products, diagnostics and Software as a Medical Device (SaMD solutions). BrightInsight replaces the need for lengthy and complex ‘build from scratch’ implementations by offering configurable software solutions and a proven platform built under a Quality Management System to support global security, privacy and regulatory requirements. When building digital health products on the BrightInsight Platform, compliance is future-proofed as intended use changes scale across geographies.

For more information, visit BrightInsight’s websiteBlogTwitter, and LinkedIn pages.

 

SOURCE Frost & Sullivan

Malaysia Healthcare Travel Council Denies Allegations of Lack Of Direction in the Company

KUALA LUMPUR, Malaysia, March 02, 2024 (GLOBE NEWSWIRE) — M

World Trade Organization Continues to Allow Subsidized Overfishing

WASHINGTON, March 01, 2024 (GLOBE NEWSWIRE) — This week, at

澳門2023年GDP增長80.5%

澳門統計暨普查局資料顯示,隨着本地經濟活動及服務出口有序復常,2023年澳門本地生產總值(GDP)錄得實質增長80.5%。

新發展 新空間 新動能——澳門各界歡迎橫琴正式封關運行

新華社澳門3月1日電 題:新發展 新空間 新動能——澳門各界歡迎橫琴正式封關運行

Veracio to Unveil their Next Generation of Orebody Technology Tools to Transform Mineral Exploration and Mining

SALT LAKE CITY, March 01, 2024 (GLOBE NEWSWIRE) —  Veracio,

Acronis Announces #TeamUp Partnership with Digacore and the New York Yankees

NEW YORK, March 01, 2024 (GLOBE NEWSWIRE) — Acronis, a glob

【特刊】二萬港元?

港府自去年10月起為每名新生兒提供二萬港元獎勵金。專家接受記者採訪時稱,此舉浪費公帑。 

“一國兩制”新實踐!橫琴正式封關運行

新華社廣州3月1日電(記者周強、王浩明)作為中國實施高水準制度型開放的重大探索,橫琴粵澳深度合作區3月1日零時正式實施封關運行,這標誌著構建與澳門一體化高水準開放新體系邁出關鍵一步,有助於豐富“一國兩制”實踐探索,更好推動澳門融入國家發展大局。

ATHA Energy Announces Approval to List on TSXV and Receipt of Final Order for Arrangement With Latitude Uranium

VANCOUVER, British Columbia, March 01, 2024 (GLOBE NEWSWIRE)

相關文章

【特刊】政府能如何更進一步?

仍然可以採取很多措施;但實際成效仍有待觀察。社會各有各說法,意見分歧。

澳門2024年GDP預計按年增一成

澳門經濟財政司司長李偉農預計2024年澳門本地生產總值(GDP)按年實質增長率可達10.3%,恢復至2019年水平約九成。

澳門1月入境旅客量恢復至疫前水平83.5%

澳門統計暨普查局資料顯示,今年1月入境旅客按年增加一倍至2,861,609人次,恢復至2019年同期83.5%。1月錄得199,278人次國際旅客,恢復至2019年同期的66.4%。

【特刊】龍年嬰兒潮:1988 年和 2012 年(2000年除外)

2000年經濟衰退期間,圍繞龍寶寶的吉祥信念並沒有成功緩解父母對生育的擔憂。

政府公佈輕軌行車系統營運36.6億元合同判給結果

澳門政府將“輕軌東線之行車系統”判予三家實體合作經營,判給金額達澳門幣36.57億元(折合約4.6 億美元)。

春節黃金周首五天近90萬旅客訪澳

春節黃金周僅五天,澳門已接待入境旅客898,665人次。週三(年初五、2月14日)勢頭十足,錄得入境旅客達195,567人次。八日春節黃金周的訪澳旅客總數有望超過旅遊局最初預估的96萬人次。